Novo Nordisk Collaborates with US Biotech Firm to Develop Innovative Obesity Medications
Novo Nordisk and Septerna have embarked on a groundbreaking partnership to develop oral medications targeting GPCRs for obesity and metabolic diseases, promising more convenient treatment options.
Danish pharmaceutical company Novo Nordisk has announced a strategic partnership with the California-based biotech firm Septerna to develop new oral medications targeting obesity, type 2 diabetes, and other metabolic disorders. The alliance aims to harness Septerna’s expertise in drug discovery focused on G protein-coupled receptors (GPCRs), proteins crucial for transmitting signals from outside the cell to its interior. Many current widely used drugs act on GPCRs, highlighting their importance in therapeutic development.
This collaboration could be worth up to $2.2 billion, with nearly $200 million in upfront payments and additional milestones linked to research, development, and sales. Septerna will also earn royalties on future product revenues. Novo Nordisk will fund all research and development efforts related to these projects.
Septerna’s platform specifically targets GPCRs involved in blood sugar regulation and appetite control, including GLP-1, GIP, and glucagon receptors. Notably, Novo Nordisk’s well-known weight-loss drug Wegovy targets the GLP-1 receptor, while Eli Lilly’s Zepbound acts on both GLP-1 and GIP receptors.
According to Marcus Schindler, Novo Nordisk's Chief Scientific Officer, Septerna has demonstrated strong capabilities in GPCR drug discovery, which excites the company about developing small oral molecules targeting these receptors. The planned programs aim to produce pills that could replace current injectable weight-loss therapies, making treatment more accessible and convenient for patients.
With approximately 75% of GPCRs still unexplored for therapeutic use, this partnership presents significant opportunities for novel drug development. The deal has positively impacted stock prices, with Septerna’s shares jumping 69% pre-market, and Novo Nordisk’s shares seeing a modest rise in European markets.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Revolutionary Brain Wave Discovery Challenges Traditional Views of Electroconvulsive Therapy (ECT)
New research from the University of Pennsylvania uncovers that beyond seizure induction, ECT triggers cortical spreading depolarization, offering a 'hard reset' for the brain and opening pathways for more personalized and effective treatment approaches.
Cybersecurity Risks of Large Language Models in Radiology: A Special Report
A new report explores cybersecurity vulnerabilities in large language models used in radiology and highlights the importance of implementing security measures to protect patient data and clinical workflows.
Air Pollution's Impact on Bone Health in Postmenopausal Women
Emerging research reveals that long-term exposure to air pollution may accelerate bone loss in postmenopausal women, highlighting the importance of environmental health for bone integrity.
Research Links Night Shift Work in Women to Increased Asthma Risk
A new study reveals that women working night shifts are at a significantly higher risk of developing moderate to severe asthma, highlighting the need for further research into hormonal and circadian influences.